Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load

Neurology

Volumn 88, Issue 6, 2017, Pages 569-576

  Grothe, Michel J ^a   Villeneuve, Sylvia ^b,c   Dyrba, Martin ^a   Bartrés Faz, David ^d   Wirth, Miranka ^e  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TAU PROTEIN; BIOLOGICAL MARKER; RADIOPHARMACEUTICAL AGENT;

AGE; AGED; ARTICLE; BRAIN DISEASE; BRAIN METABOLISM; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE AGING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; FEMALE; GENOTYPE; GLUCOSE METABOLISM; GRAY MATTER; HETEROZYGOTE; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIMODAL IMAGING; NEUROBIOLOGY; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; TAUOPATHY; AGING; BRAIN; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; ORGAN SIZE; PATHOLOGY;

AGED; AGING; AMYLOID; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; BIOMARKERS; BRAIN; COGNITIVE DYSFUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; GRAY MATTER; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; NEUROIMAGING; ORGAN SIZE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 85011690595     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003585     Document Type: Article

References (40)

1. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-184.
2. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis: APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
3. Blair CK, Folsom AR, Knopman DS, Bray MS, Mosley TH, Boerwinkle E. APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005;64:268-276.
4. Wilson RS, Bienias JL, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry 2002;73:672-677.
5. Fouquet M, Besson FL, Gonneaud J, La Joie R, Chetelat G. Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Neuropsychol Rev 2014;24: 290-299.
6. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004;62:1977-1983.
7. Toledo JB, Zetterberg H, van Harten AC, et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain 2015;138:2701-2715.
8. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924-1938.
9. Suri S, Heise V, Trachtenberg AJ, Mackay CE. The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE e2. Neurosci Biobehav Rev 2013;37:2878-2886.
10. Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD. Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 1997;48:515-519.
11. Chiang GC, Insel PS, Tosun D, et al. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology 2010;75:1976-1981.
12. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
13. Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, et al. APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms. Mol Psychiatry 2014;19:1243-1250.
14. den Heijer T, Oudkerk M, Launer LJ, van Duijn CM, Hofman A, Breteler MM. Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology 2002;59:746-748.
15. Hostage CA, Roy Choudhury K, Doraiswamy PM, Petrella JR. Dissecting the gene dose-effects of the APOE e4 and e2 alleles on hippocampal volumes in aging and Alzheimer's disease. PLoS One 2013;8:e54483.
16. Shu H, Shi Y, Chen G, et al. Opposite neural trajectories of apolipoprotein E e4 and e2 alleles with aging associated with different risks of Alzheimer's disease. Cereb Cortex 2016;26:1421-1429.
17. Teipel S, Grothe MJ. Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease? Eur J Nucl Med Mol Imaging 2016;43:526-536.
18. Risacher SL, Kim S, Nho K, et al. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement 2015;11: 1417-1429.
19. Liu Y, Tan L, Wang HF, et al. Multiple effect of APOE genotype on clinical and neuroimaging biomarkers across Alzheimer's disease spectrum. Mol Neurobiol 2016;53: 4539-4547.
20. Crane PK, Carle A, Gibbons LE, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6:502-516.
21. Grothe M, Heinsen H, Teipel S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol Aging 2013;34:1210-1220.
22. Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571-583.
23. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015;138:2020-2033.
24. Kljajevic V, Grothe MJ, Ewers M, Teipel S. Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease. Neurobiol Aging 2014; 35:1973-1981.
25. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009;65:403-413.
26. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-b peptide clearance. Sci Transl Med 2011;3:89ra57.
27. Fan M, Liu B, Zhou Y, et al. Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults. Neurosci Lett 2010;479:332-336.
28. Trachtenberg AJ, Filippini N, Ebmeier KP, Smith SM, Karpe F, Mackay CE. The effects of APOE on the functional architecture of the resting brain. Neuroimage 2012; 59:565-572.
29. Wolf AB, Valla J, Bu G, et al. Apolipoprotein E as a b-amyloid-independent factor in Alzheimer's disease. Alzheimers Res Ther 2013;5:38.
30. Jagust WJ, Landau SM; Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012;32:18227-18233.
31. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE e4 effects on memory, brain structure, and b-amyloid across the adult life span. JAMA Neurol 2015;72:511-519.
32. Sorg C, Grothe MJ. The complex link between amyloid and neuronal dysfunction in Alzheimer's disease. Brain 2015;138:3472-3475.
33. Westlye LT, Reinvang I, Rootwelt H, Espeseth T. Effects of APOE on brain white matter microstructure in healthy adults. Neurology 2012;79:1961-1969.
34. Suri S, Mackay CE, Kelly ME, et al. Reduced cerebrovascular reactivity in young adults carrying the APOE e4 allele. Alzheimers Dement 2015;11:648-657.e1.
35. Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87:539-547.
36. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-192.
37. Alexopoulos P, Kriett L, Haller B, et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. Alzheimers Dement 2014; 10:684-689.
38. Ramanan VK, Risacher SL, Nho K, et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry 2014;19:351-357.
39. Biffi A, Anderson CD, Desikan RS, et al. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol 2010;67:677-685.
40. Desikan RS, Schork AJ, Wang Y, et al. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry 2015;20:1588-1595.